Cetera Investment Advisers Sells 6,133 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)

Cetera Investment Advisers trimmed its position in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) by 23.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 20,237 shares of the company’s stock after selling 6,133 shares during the period. Cetera Investment Advisers’ holdings in Checkpoint Therapeutics were worth $65,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. Stifel Financial Corp bought a new position in Checkpoint Therapeutics during the fourth quarter worth about $32,000. PUREfi Wealth LLC bought a new position in Checkpoint Therapeutics during the fourth quarter worth about $32,000. SBI Securities Co. Ltd. bought a new position in Checkpoint Therapeutics during the fourth quarter worth about $32,000. Tower Research Capital LLC TRC lifted its holdings in Checkpoint Therapeutics by 157.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,616 shares of the company’s stock worth $34,000 after acquiring an additional 6,486 shares in the last quarter. Finally, Boothbay Fund Management LLC bought a new position in Checkpoint Therapeutics during the fourth quarter worth about $35,000. 22.00% of the stock is currently owned by institutional investors.

Checkpoint Therapeutics Price Performance

Shares of NASDAQ:CKPT opened at $4.26 on Tuesday. The company has a market capitalization of $370.71 million, a P/E ratio of -2.32 and a beta of 1.18. Checkpoint Therapeutics, Inc. has a 1 year low of $1.80 and a 1 year high of $4.50. The business’s 50 day simple moving average is $4.10 and its 200 day simple moving average is $3.68.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its earnings results on Tuesday, May 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.09). On average, sell-side analysts anticipate that Checkpoint Therapeutics, Inc. will post -0.94 EPS for the current fiscal year.

Insider Activity at Checkpoint Therapeutics

In other news, CEO James F. Oliviero III sold 15,090 shares of the company’s stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $4.04, for a total value of $60,963.60. Following the completion of the sale, the chief executive officer now directly owns 3,759,929 shares in the company, valued at $15,190,113.16. This represents a 0.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO William Garrett Gray sold 12,322 shares of the company’s stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $4.05, for a total transaction of $49,904.10. Following the completion of the transaction, the chief financial officer now directly owns 1,446,322 shares of the company’s stock, valued at $5,857,604.10. This represents a 0.84% decrease in their position. The disclosure for this sale can be found here. 2.10% of the stock is owned by company insiders.

Analyst Ratings Changes

CKPT has been the topic of a number of recent research reports. Lake Street Capital reaffirmed a “hold” rating and issued a $4.10 target price (down previously from $7.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th. HC Wainwright reaffirmed a “neutral” rating and set a $4.10 price target on shares of Checkpoint Therapeutics in a research report on Tuesday, March 11th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $4.80 price target on shares of Checkpoint Therapeutics in a research report on Monday, March 31st.

Checkpoint Therapeutics Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.